KLRF1抗体;KLRF1 Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P11890(KLRF1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P11890(KLRF1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The KLRF1 (Killer Cell Lectin-Like Receptor Subfamily F Member 1) antibody targets a protein encoded by the *KLRF1* gene, which belongs to the C-type lectin-like receptor family. KLRF1. also known as NKp80. is primarily expressed on natural killer (NK) cells and a subset of CD8+ T cells. It functions as an activating receptor involved in immune surveillance and cytotoxicity. Structurally, KLRF1 contains a extracellular C-type lectin-like domain, a transmembrane region, and a short cytoplasmic tail lacking intrinsic signaling motifs. Instead, it associates with adaptor proteins like DAP12 to mediate signaling, enhancing NK cell activation, cytokine production, and target cell killing.

KLRF1 interacts with its ligand, activation-induced C-type lectin (AICL), expressed on myeloid cells, facilitating NK cell adhesion and triggering cytotoxic responses. This interaction plays a role in immune regulation, particularly in viral infections and cancer. Antibodies against KLRF1 are valuable tools for studying NK cell biology, immune activation mechanisms, and receptor-ligand dynamics. They are used in flow cytometry, immunohistochemistry, and functional assays to explore KLRF1's role in diseases like leukemia, chronic infections, and autoimmune disorders. Additionally, therapeutic applications are being investigated, such as modulating NK cell activity in immunotherapy. Commercial KLRF1 antibodies are typically monoclonal, validated for specificity in human or murine models, and serve as critical reagents in both basic research and clinical diagnostics.